Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.$Novo-Nordisk A/S (NVO.US)$, the Danish pharmaceutical company, saw its market value soar to $506 billion on Wednesday following the release of its 2023 earnings, driven by a surge in demand for its key drugs in the past quarter.
$诺和诺德 (NVO.US)$这家丹麦制药公司在公布2023年财报后，周三其市值飙升至5,060亿美元，这得益于上个季度对其关键药物的需求激增。
This increase in value was attributed to the high demand for Novo Nordisk's weight loss drug, Wegovy, and diabetes drug, Ozempic.
价值的增长归因于对诺和诺德的减肥药物Wegovy和糖尿病药物Ozempic的高需求。
Novo Nordisk's 2023 sales rose by 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion). The full-year operating profit also significantly increased, rising by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner.
诺和诺德2023年的销售额以丹麦克朗计算增长了31％，按固定汇率（CER）计算增长了36％，达到2323亿克朗（合337.1亿美元）。全年营业利润也大幅增长，按克朗计算增长了37％，按固定汇率计算增长了44％，达到1,026亿克朗。
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient.
该公司预测，按恒定汇率计算，本年度的销售额将增长18％至26％，这要归因于对含有相同活性成分的Wegovy和Ozempic的需求激增。
Novo Nordisk's 2023 results were largely influenced by the strong performance of its diabetes and obesity care division, with obesity care experiencing a 154% spike at CER to 41.6 billion.
诺和诺德2023年的业绩在很大程度上受到其糖尿病和肥胖症护理部门的强劲表现的影响，按CER计算，肥胖症护理增长了154％，达到416亿。
The surge in demand for Novo Nordisk's drugs comes amid reports of counterfeit versions of its medications. The rising demand for Ozempic and its sister medication, Wegovy, has led to reports of salons and social media distributors selling knockoff versions.
对Novo Nordisk药品的需求激增之际，有报道称其药物存在假冒版本。对Ozempic及其姊妹药物Wegovy的需求不断增加，导致有报道称沙龙和社交媒体分销商出售仿冒品。
Despite this, the company's market value has continued to rise, with notable investors taking a bullish stance on Novo Nordisk's options. This suggests that the market is confident in the company's ability to maintain its growth trajectory.
尽管如此，该公司的市值仍在持续上涨，知名投资者对诺和诺德的期权持看涨立场。这表明市场对公司维持增长轨迹的能力充满信心。
Novo Nordisk's CEO, Lars Fruergaard Jørgensen, acknowledged the emergence of competition in the weight-loss market, particularly from U.S. stalwart Eli Lilly. Jørgensen believes that this competition will ultimately benefit patients and drive further growth in the obesity care market.
诺和诺德首席执行官拉斯·弗鲁尔加德·约根森承认减肥市场出现了竞争，特别是来自美国巨头礼来公司的竞争。约根森认为，这场竞争最终将使患者受益，并推动肥胖症护理市场的进一步增长。
Despite potential price pressures from this competition, Novo Nordisk remains confident in the continued global demand for its products. The company is investing heavily in expanding its production capacity to meet this demand, with construction already underway on several projects.
尽管这场竞争可能带来价格压力，但诺和诺德对全球对其产品的持续需求仍然充满信心。该公司正在大力投资扩大其生产能力以满足这一需求，多个项目已经在建设中。